According to a new report published by K D Market Insights, titled, “Hemophilia Market Insights, Trends, Opportunity & Forecast, 2023–2032,” the global hemophilia market size is anticipated to witness moderate growth during the forecast period i.e., 2023-2032. The increasing prevalence of hemophilia and related bleeding disorders, advancements in hemophilia treatment options, and the rising awareness about the condition which are the major factors augmenting the growth of the global hemophilia market. The global hemophilia market is anticipated to grow at a robust CAGR of 5.7% from 2023 to 2032. It achieved a revenue of $12.6 billion in 2022 and is projected to reach $21.9 billion by 2032.
The rising awareness about hemophilia and advancements in diagnostic techniques have led to an early diagnosis and treatment initiation are further expected to create ample growth opportunities for the global hemophilia market during the forecast period i.e., 2023-2032. Moreover, Advancements in hemophilia treatment options, including clotting factor replacements, gene therapies, and non-replacement therapies, have significantly improved patient outcomes has propelled market expansion. Continuous investments in research and development (R&D) activities, is expected to contribute towards the market growth during the period.
The North America region accounted for the largest share in the global hemophilia market in 2022. The region is further projected to continue dominating in the market during the forecast period. This can be attributed to the high prevalence of hemophilia, coupled with favorable healthcare policies.
According to type, the Hemophilia A segment accounted for the largest market share in the hemophilia market in 2022 and is further expected to continue with the trend during the forecast period i.e., 2023 – 2032.
The global hemophilia market is segmented into type, treatment type, therapy and region. Based on type, the market is bifurcated into hemophilia a, hemophilia b, others. Based on treatment type, it is classified into on-demand, cure, prophylaxis. Based on therapy, it is classified into factor replacement therapy, plasma-derived factor concentrates, recombinant factor concentrates, desmopressin & fibrin sealants, gene therapy & monoclonal antibodies.
The global hemophilia market is analyzed across North America (U.S. & Canada), Europe (Germany, United Kingdom, France, Italy, Spain, Russia, and Rest of Europe), Asia Pacific (China, India, Japan, South Korea, Indonesia, Thailand, Australia, New Zealand, and Rest of Asia Pacific), Latin America (Brazil, Mexico, and the Rest of Latin America) and Middle East & Africa (GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa, and Rest of Middle East & Africa).
Key Insights of Hemophilia Market
- On the basis of type, the Hemophilia A segment accounted for the largest market share in the hemophilia market in 2022 and is further expected to continue with the trend during the forecast period i.e., 2023 – 2032.
- On the basis of region, North America accounted for the largest share in the global hemophilia market in 2022. The region is further projected to continue dominating in the market during the forecast period.
- On the basis of region, Asia-Pacific is estimated to account for the second largest share in the market during the forecast period.
Some of the major hemophilia companies profiled in the report include Takeda Pharmaceutical Company Limited, CSL Behring, Pfizer, Inc., Bayer AG, BioMarin, Spark Therapeutics, Inc., Sanofi, F. Hoffmann La-Roche Ltd., Novo Nordisk A/S, and Octapharma AG.
Related Healthcare Reports :-
https://www.kdmarketinsights.com/reports/sinusitis-treatment-market/7121
https://www.kdmarketinsights.com/reports/urea-cycle-disorder-treatment-market/7120
https://www.kdmarketinsights.com/reports/vertigo-treatment-market-1/7119
https://www.kdmarketinsights.com/reports/fusion-inhibitors-market/7117
